Literature DB >> 25415716

Characterization of liver function parameter alterations after transjugular intrahepatic portosystemic shunt creation and association with early mortality.

Leigh C Casadaban1, Ahmad Parvinian, Patrick M Couture, Jeet Minocha, M Grace Knuttinen, James T Bui, Ron C Gaba.   

Abstract

OBJECTIVE: The purpose of this article is to characterize the temporal evolution and clinical impact of laboratory liver function parameters after transjugular intrahepatic portosystemic shunt (TIPS) creation.
MATERIALS AND METHODS: In this single-institution retrospective study, 157 patients (98 men and 59 women; median age, 55 years) underwent TIPS between 2000 and 2012 and had 1-month hepatobiliary laboratory follow-up. Medical record review was used to compare baseline, peak, and low bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase, and international normalized ratio (INR) levels within 30 days after TIPS in surviving and dying patients to assess laboratory responses to shunt creation.
RESULTS: TIPSs were created with a hemodynamic success rate of 98%, with median pressure gradient reduction of 13 mm Hg. Ninety-day mortality was 21%. Hepatobiliary laboratory values showed significant increases in the days after TIPS compared with baseline levels (bilirubin, 1.6 vs 3.5 mg/dL; AST, 49 vs 149 U/L; ALT, 26 vs 90 U/L; alkaline phosphatase, 97 vs 177 U/L; and INR, 1.5 vs 2.0; p<0.05 in all cases). Patients surviving to 90 days experienced statistically significant but transient laboratory value elevations-up to twofold over baseline-within days of TIPS, whereas patients dying within 90 days experienced three-to fourfold increases over a longer period that did not return to baseline. Differences in laboratory evolution were statistically significant in surviving versus dying patients.
CONCLUSION: TIPS results in acute transient elevation of hepatobiliary enzymes, which may be more pronounced in patients with early mortality. An exaggerated laboratory elevation in excess of threefold greater than baseline or a prolonged increase exceeding 1 week may herald poorer clinical outcome.

Entities:  

Keywords:  laboratory; liver function parameters; mortality; transjugular intrahepatic portosystemic shunt

Mesh:

Year:  2014        PMID: 25415716     DOI: 10.2214/AJR.13.12232

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  9 in total

1.  Incidence of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt (TIPS) according to its severity and temporal grading classification.

Authors:  Paolo Fonio; Andrea Discalzi; Marco Calandri; Andrea Doriguzzi Breatta; Laura Bergamasco; Silvia Martini; Antonio Ottobrelli; Dorico Righi; Giovanni Gandini
Journal:  Radiol Med       Date:  2017-05-16       Impact factor: 3.469

2.  Budd-Chiari syndrome: consensus guidance of the Asian Pacific Association for the study of the liver (APASL).

Authors:  Akash Shukla; Ananta Shreshtha; Amar Mukund; Chhagan Bihari; C E Eapen; Guohong Han; Hemant Deshmukh; Ian Homer Y Cua; Cosmas Rinaldi Adithya Lesmana; Mamun Al Meshtab; Masayoshi Kage; Roongruedee Chaiteeraki; Sombat Treeprasertsuk; Suprabhat Giri; Sundeep Punamiya; Valerie Paradis; Xingshun Qi; Yasuhiko Sugawara; Zaigham Abbas; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-07-08       Impact factor: 6.047

Review 3.  Hospice care for end stage liver disease in the United States.

Authors:  Eric S Orman; Amy W Johnson; Marwan Ghabril; Greg A Sachs
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2021-02-24       Impact factor: 4.095

4.  Efficacy and safety of laparoscopic splenectomy for hypersplenism secondary to portal hypertension after transjugular intrahepatic portosystemic shunt.

Authors:  Yingying Li; Zuojin Liu; Chang'an Liu
Journal:  BMC Gastroenterol       Date:  2021-02-11       Impact factor: 3.067

Review 5.  TIPS and splenorenal shunt for complications of portal hypertension in chronic hepatosplenic schistosomiasis-A case series and review of the literature.

Authors:  Tamara Nordmann; Stefan Schlabe; Torsten Feldt; Federico Gobbi; Andreas Krieg; Johannes G Bode; Andre Fuchs; Christian Kraef; Michael Praktiknjo; Jonel Trebicka; Michael Ramharter; Marylyn M Addo; Christian Strassburg; Ansgar W Lohse; Tom Luedde; Stefan Schmiedel; Hans Martin Orth
Journal:  PLoS Negl Trop Dis       Date:  2021-12-21

Review 6.  State of the Art, Current Perspectives, and Controversies of Budd-Chiari Syndrome: A Review.

Authors:  Paschalis Gavriilidis; Gabriele Marangoni; Jawad Ahmad; Daniel Azoulay
Journal:  J Clin Med Res       Date:  2022-04-30

7.  Covered TIPS Procedure-Related Major Complications: Incidence, Management and Outcome From a Single Center.

Authors:  Xiaochun Yin; Lihong Gu; Ming Zhang; Qin Yin; Jiangqiang Xiao; Yi Wang; Xiaoping Zou; Feng Zhang; Yuzheng Zhuge
Journal:  Front Med (Lausanne)       Date:  2022-05-04

8.  Effects of a Long-Acting Formulation of Octreotide on Patients with Portal Hypertension.

Authors:  Pei-Jing Cui; Jing Yao; Yin Zhu; Zheng-Yun Zhang; Jun Yang
Journal:  Gastroenterol Res Pract       Date:  2017-08-10       Impact factor: 2.260

Review 9.  Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.

Authors:  Sasidharan Rajesh; Tom George; Cyriac Abby Philips; Rizwan Ahamed; Sandeep Kumbar; Narain Mohan; Meera Mohanan; Philip Augustine
Journal:  World J Gastroenterol       Date:  2020-10-07       Impact factor: 5.742

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.